217 related articles for article (PubMed ID: 18321484)
1. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets.
Stockwell KA; Virley DJ; Perren M; Iravani MM; Jackson MJ; Rose S; Jenner P
Exp Neurol; 2008 May; 211(1):172-9. PubMed ID: 18321484
[TBL] [Abstract][Full Text] [Related]
2. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
Jackson MJ; Smith LA; Al-Barghouthy G; Rose S; Jenner P
Exp Neurol; 2007 Mar; 204(1):162-70. PubMed ID: 17113078
[TBL] [Abstract][Full Text] [Related]
3. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Pearce RK; Banerji T; Jenner P; Marsden CD
Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
[TBL] [Abstract][Full Text] [Related]
4. The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
Zubair M; Jackson MJ; Tayarani-Binazir K; Stockwell KA; Smith LA; Rose S; Olanow W; Jenner P
Exp Neurol; 2007 Dec; 208(2):177-84. PubMed ID: 17935716
[TBL] [Abstract][Full Text] [Related]
5. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets.
Johnston LC; Jackson MJ; Rose S; McCreary AC; Jenner P
Mov Disord; 2010 Oct; 25(13):2059-66. PubMed ID: 20721904
[TBL] [Abstract][Full Text] [Related]
6. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
Tayarani-Binazir K; Jackson MJ; Rose S; McCreary AC; Jenner P
Exp Neurol; 2010 Dec; 226(2):320-7. PubMed ID: 20843474
[TBL] [Abstract][Full Text] [Related]
7. Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.
Tayarani-Binazir KA; Jackson MJ; Rose S; Olanow CW; Jenner P
Mov Disord; 2010 Feb; 25(3):377-84. PubMed ID: 20108359
[TBL] [Abstract][Full Text] [Related]
8. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.
Smith LA; Jackson MJ; Johnston L; Kuoppamaki M; Rose S; Al-Barghouthy G; Del Signore S; Jenner P
Clin Neuropharmacol; 2006; 29(3):112-25. PubMed ID: 16772809
[TBL] [Abstract][Full Text] [Related]
9. Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or L-DOPA in MPTP-treated common marmosets.
Stockwell KA; Scheller DK; Smith LA; Rose S; Iravani MM; Jackson MJ; Jenner P
Exp Neurol; 2010 Jan; 221(1):79-85. PubMed ID: 19833125
[TBL] [Abstract][Full Text] [Related]
10. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
Smith LA; Tel BC; Jackson MJ; Hansard MJ; Braceras R; Bonhomme C; Chezaubernard C; Del Signore S; Rose S; Jenner P
Mov Disord; 2002 Sep; 17(5):887-901. PubMed ID: 12360537
[TBL] [Abstract][Full Text] [Related]
11. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.
Stockwell KA; Scheller D; Rose S; Jackson MJ; Tayarani-Binazir K; Iravani MM; Smith LA; Olanow CW; Jenner P
Exp Neurol; 2009 Oct; 219(2):533-42. PubMed ID: 19619533
[TBL] [Abstract][Full Text] [Related]
12. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets.
Pearce RK; Smith LA; Jackson MJ; Banerji T; Scheel-Krüger J; Jenner P
Mov Disord; 2002 Sep; 17(5):877-86. PubMed ID: 12360536
[TBL] [Abstract][Full Text] [Related]
13. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
[TBL] [Abstract][Full Text] [Related]
14. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
[TBL] [Abstract][Full Text] [Related]
15. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
Maratos EC; Jackson MJ; Pearce RK; Jenner P
Mov Disord; 2001 Jul; 16(4):631-41. PubMed ID: 11481686
[TBL] [Abstract][Full Text] [Related]
16. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
Smith LA; Jackson MJ; Al-Barghouthy G; Rose S; Kuoppamaki M; Olanow W; Jenner P
Mov Disord; 2005 Mar; 20(3):306-14. PubMed ID: 15490461
[TBL] [Abstract][Full Text] [Related]
17. A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs.
Mihara T; Iwashita A; Matsuoka N
Behav Brain Res; 2008 Dec; 194(2):152-61. PubMed ID: 18657577
[TBL] [Abstract][Full Text] [Related]
18. Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets.
Lincoln L; Fisher R; Jackson MJ; Jenner P; Neumeyer J; Sromek AW; Lees AJ; Rose S
Mov Disord; 2016 Sep; 31(9):1381-8. PubMed ID: 27133947
[TBL] [Abstract][Full Text] [Related]
19. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P
Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948
[TBL] [Abstract][Full Text] [Related]
20. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
